HR Execs on the Move

F1 Oncology

www.f1oncology.com

 
We are harnessing the power of the immune system to target some of the most challenging solid tumor malignancies.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Libra Therapeutics

Libra Therapeutics is focused on developing novel disease-modifying therapeutics that can restore the cellular balance disrupted in neurodegenerative diseases.

LifeServe Blood Center

LifeServe Blood Center is a Des Moines, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aytu BioScience

Aytu BioScience, Inc. is a specialty healthcare company focused on developing treatments for urological and related conditions. The Company is currently completing Phase 3 clinical development for its lead therapeutic candidate Zertane™, an orally disintegrating tablet (ODT) formulated specifically for the on-demand treatment of premature ejaculation (PE). The Company`s therapeutic pipeline is supported in part by its first-in-class RedoxSYS® System, which provides the only complete assessment of patients` redox status and enables identification of a broad variety of disorders where redox is implicated. Clinical studies are underway utilizing the RedoxSYS system in male fertility. The Company also recently acquired and is commercializing FDA-approved ProstaScint® (capromab pendetide), a radio-labeled monoclonal antibody, that targets Prostate Specific Membrane Antigen (PSMA), a protein uniquely expressed by prostate tissue. The Company`s strategy is to develop its core therapeutic and diagnostic assets while building an innovative pipeline of established marketed products and late-stage development assets.

Mesoblast

Mesoblast is a world leader in developing innovative cellular medicines. We have established what we believe is the industry`s most clinically advanced and diverse portfolio of cell-based products with five programs, two of which are partnered, in active Phase 3 clinical studies or Phase 3-ready, and four programs in Phase 2. All our clinical programs target significant, under-served therapeutic areas including cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions.

Axol Bioscience

We specialize in human cell culture. Whether you need iPSC-derived cells, disease models, human primary cells or culture media, were here for you.